Literature DB >> 3881921

Intravenous versus intracoronary streptokinase in acute myocardial infarction.

R P Valentine, D E Pitts, J A Brooks-Brunn, J G Williams, E Van Hove, P E Schmidt.   

Abstract

One hundred sixty-four consecutive patients with acute myocardial infarction were enrolled in a prospective trial of coronary thrombolysis with streptokinase (STK). The first 98 patients received intracoronary (i.c.) STK after coronary angiography and the next 66 received a high-dose rapid infusion of STK (900,000 IU) intravenously (i.v.) before angiography. First-pass radionuclide ejection fraction (EF) was performed early (within 24 hours of admission) and late (10 to 14 days after admission) to evaluate left ventricular function. In the i.v. group, 42 of 66 (64%) of infarct-related arteries were patent at the initial angiogram and 6 (9%) opened with subsequent i.c. STK. In the i.c. group, 13 of 98 (13%) of infarct-related arteries were patent at the initial angiogram and 50 of 85 (59%) opened with the i.c. STK. The i.v. and i.c. groups did not differ in time from onset of chest pain to presentation, type of infarct or underlying severity of coronary artery disease. In the i.v. group, STK was begun 67 minutes earlier than in the i.c. group. In 62 patients in whom reperfusion was successful, mean EF increased from 39 +/- 11% early to 48 +/- 13% late. In 30 in whom it was not, the mean EF increased from 36 +/- 10% to 40 +/- 12%. The increase in EF was significantly greater in patients in the reperfused group (p less than 0.03). In 18 patients who underwent reperfusion by i.v. STK, the mean EF increased 11 +/- 12%, whereas in 44 patients who had reperfusion by i.c. STK, the mean EF increased 9 +/- 10% (difference not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881921     DOI: 10.1016/0002-9149(85)90366-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?

Authors:  W Kasper; T Meinertz; H Just
Journal:  Klin Wochenschr       Date:  1986-04-01

4.  Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  C Bucknall; C Darley; J Flax; R Vincent; D Chamberlain
Journal:  Br Heart J       Date:  1988-01

Review 5.  Cardiac ischemia. Part II--Reperfusion and treatment.

Authors:  G A Langer; G D Buckberg; J H Tillisch
Journal:  West J Med       Date:  1987-07

6.  Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology.

Authors:  Adnan I Qureshi; Foad Abd-Allah; Aitziber Aleu; John J Connors; Ricardo A Hanel; Ameer E Hassan; Haitham M Hussein; Nazli A Janjua; Rakesh Khatri; Jawad F Kirmani; Mikael Mazighi; Heinrich P Mattle; Jefferson T Miley; Thanh N Nguyen; Gustavo J Rodriguez; Qaisar A Shah; Adnan H Siddiqui; Jose I Suarez; M Fareed K Suri; Reha Tolun
Journal:  J Vasc Interv Neurol       Date:  2014-05

7.  A history of streptokinase use in acute myocardial infarction.

Authors:  Nikhil Sikri; Amit Bardia
Journal:  Tex Heart Inst J       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.